India’s DBT, Bharat Biotech announce positive Phase III clinical trial resutls of rotavirus vaccine

May 15, 2013

The clinical study demonstrates for the first time that the India-developed rotavirus vaccine ROTAVAC- is efficacious in preventing severe rotavirus diarrhoea in low-resource settings in India. ROTAVAC- significantly reduced severe rotavirus diarrhoea by more than half-56 percent during the first year of life, with protection continuing into the second year of life. Moreover, the vaccine also showed impact against severe diarrhoea of any cause. (News-Medical)